Crossmark

Effects of benfotiamine treatment over 12 months on morphometric, neurophysiological and clinical measures in type 2 diabetes patients with symptomatic polyneuropathy: a randomized, placebo-controlled, double-blind clinical trial (BOND study)

Crossref DOI link: https://doi.org/10.1136/bmjdrc-2025-005773

Published Online: 2026-01-22

Published Print: 2026-01

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Ziegler, Dan https://orcid.org/0000-0001-8956-3552
Sipola, Gundega https://orcid.org/0009-0006-7638-0638
Strom, Alexander

Strassburger, Klaus https://orcid.org/0000-0002-6636-1373
Jander, Luise

Herder, Christian https://orcid.org/0000-0002-2050-093X
Knebel, Birgit https://orcid.org/0000-0002-5575-4315
Reule, Claudia https://orcid.org/0009-0000-3234-6987
Jaghutriz, Benjamin Assad

Moreira Tupac Yupanqui, Andrea Carolina https://orcid.org/0009-0005-8153-7428
Icks, Andrea https://orcid.org/0000-0002-4882-969X
Al-Hasani, Hadi https://orcid.org/0000-0003-2543-0130
Roden, Michael https://orcid.org/0000-0001-8200-6382
Kuss, Oliver https://orcid.org/0000-0003-3301-5869
Bönhof, Gidon J https://orcid.org/0000-0003-1446-6592
Funding

Funding for this research was provided by:

Wörwag Pharma GmbH & Co. KG (N/A)
License Information

License valid from 2026-01-22